The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Review of the Comparative Pharmacology and Clinical Activity of Cisplatin and Carboplatin
Abstract
PURPOSE: To review the pharmacodynamics, pharmacokinetics, toxicities, and relative clinical activities of cisplatin and carboplatin. Through a search of the MEDLINE database, we identified phase III clinical trials and pharmacologic studies comparing cisplatin and carboplatin published in the English language medical literature from January 1966 to December 1997. RESULTS: Prospective randomized trials comparing cisplatin to carboplatin were identified for ovarian (n = 12), germ cell (n = 4), non–small-cell lung (n = 1), small-cell lung (n = 3), and head and neck (n = 4) cancers. Carboplatin and cisplatin were equally effective in suboptimally debulked ovarian cancer and extensive-stage small-cell lung cancer. One study each showed a trend toward better survival in favor of cisplatin for patients with optimally debulked ovarian and limited-stage small-cell lung cancers. These results were, however, based on subset analyses. In germ cell tumors, carboplatin was inferior because of lower relapse-free survival rates. Cisplatin produced superior response rates and survival in head and neck cancers. There are no published randomized phase III studies of bladder, cervical, endometrial, and esophageal cancers. CONCLUSION: Carboplatin does not possess equivalent activity to cisplatin in all platinum-sensitive tumors. Carboplatin can replace cisplatin in chemotherapy regimens for suboptimally debulked ovarian cancer. Two ongoing studies will address the same question in optimally debulked disease. Carboplatin can also be substituted for cisplatin in the treatment of non–small-cell and extensive-stage small-cell lung cancers. Its role in limited-stage small-cell lung cancer needs to be investigated further. Carboplatin is inferior to cisplatin in germ cell, head and neck, and esophageal cancers. Randomized studies are needed to determine whether carboplatin has equivalent efficacy to cisplatin in bladder, cervical, and endometrial cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inhibition of Cell Division in Escherichia coli by Electrolysis Products from a Platinum Electrode
ROSENBERG, B., VAN CAMP, L., & KRIGAS, T. (1965) · Nature · doi:10.1038/205698a0 · Cited by 3,049
Non-small Cell Lung Cancer Collaborative Group (1995) · BMJ · doi:10.1136/bmj.311.7010.899 · Cited by 2,850
(1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.2.594 · Cited by 1,929
Carboplatin dosage: prospective evaluation of a simple formula based on renal function.
Calvert, A. H., Newell, D. R., Gumbrell, L. A., O'Reilly, S., Burnell, M., Boxall, F. E., Siddik, Z. H., Judson, I. R., Gore, M. E., & Wiltshaw, E. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.11.1748 · Cited by 1,866
Loehrer, P. J., Einhorn, L. H., Elson, P. J., Crawford, E. D., Kuebler, P., Tannock, I., Raghavan, D., Stuart-Harris, R., Sarosdy, M. F., & Lowe, B. A. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.7.1066 · Cited by 981
Le Chevalier, T., Brisgand, D., Douillard, J. Y., Pujol, J. L., Alberola, V, Monnier, A., Riviere, A., Lianes, P., Chomy, P., & Cigolari, S. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.2.360 · Cited by 811
Gralla, R. J., Itri, L. M., Pisko, S. E., Squillante, A. E., Kelsen, D. P., Braun, D. W., Bordin, L. A., Braun, T. J., & Young, C. W. (1981) · New England Journal of Medicine · doi:10.1056/nejm198110153051601 · Cited by 705
The role of DNA mismatch repair in platinum drug resistance.
Fink, D. A., Nebel, S., Aebi, S. P., Zheng, H., Cenni, B., Nehmé, A., Christen, R. D., & Howell, S. B. (1996) · PubMed · Cited by 597
Cellular accumulation of the anticancer agent cisplatin: A review
Gately, D., & Howell, S. (1993) · British Journal of Cancer · doi:10.1038/bjc.1993.221 · Cited by 572
Ishikawa, T., & Ali-Osman, F. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(20)80702-9 · Cited by 533
Knox, R. J., Friedlos, F., Lydall, D. A., & Roberts, J. J. (1986) · PubMed · Cited by 498
Kemp, G., Rose, P., Lurain, J., Berman, M., Manetta, A., Roullet, B., Homesley, H., Belpomme, D., & Glick, J. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.7.2101 · Cited by 463
Binding of the antitumor drug cis-diamminedichloroplatinum(II) (cisplatin) to DNA
Pinto, A. L., & Lippard, S. J. (1985) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/0304-419x(85)90001-0 · Cited by 437
Sequences of taxol and cisplatin: a phase I and pharmacologic study.
Rowinsky, E. K., Gilbert, M. R., McGuire, W. P., Noe, D. A., Grochow, L. B., Forastiere, A. A., Ettinger, D. S., Lubejko, B. G., Clark, B., & Sartorius, S. E. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.9.1692 · Cited by 426
Rosenberg, B., Van Camp, L., Grimley, E. B., & Thomson, A. J. (1967) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)96186-7 · Cited by 420
Gregg, R. W., Molepo, J. M., Monpetit, V. J., Mikael, N. Z., Redmond, D., Gadia, M., & Stewart, D. J. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.5.795 · Cited by 358
Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function
KINTZEL, P. (1995) · Cancer Treatment Reviews · doi:10.1016/0305-7372(95)90010-1 · Cited by 357
Bajorin, D. F., Sarosdy, M. F., Pfister, D. G., Mazumdar, M., Motzer, R. J., Scher, H. I., Geller, N. L., Fair, W. R., Herr, H., & Sogani, P. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.4.598 · Cited by 354
Toxic effects of cis-dichlorodiammineplatinum(II) in man.
Hoff, V., Schilsky, R. L., Reichert, C. M., Rl, R., Rozencweig, M., Rc, Y., & Muggia, F. M. (1980) · PubMed · Cited by 336
High-Dose Cisplatin in Hypertonic Saline
OZOLS, R. F., CORDEN, B. J., JACOB, J., WESLEY, M. N., OSTCHEGA, Y., & YOUNG, R. C. (1984) · Annals of Internal Medicine · doi:10.7326/0003-4819-100-1-19 · Cited by 333
Horwich, A., Sleijfer, D. T., Fosså, S. D., Kaye, S. B., Oliver, R. T., Cullen, M. H., Mead, G. M., de Wit, R., de Mulder, P. H., Dearnaley, D. P., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.5.1844 · Cited by 333
Parker, R. J., Eastman, A., Bostick-Bruton, F., & Reed, E. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115080 · Cited by 299
Skarlos, D. V., Samantas, E., Kosmidis, P., Fountzilas, G., Angelidou, M., Palamidas, P. H., Mylonakis, N., Provata, A., Papadakis, E., Klouvas, G., et al. (1994) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a058931 · Cited by 274
Klastersky, J., Sculier, J. P., Lacroix, H., Dabouis, G., Bureau, G., Libert, P., Richez, M., Ravez, P., Vandermoten, G., & Thiriaux, J. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.9.1556 · Cited by 246
New platinum antitumor complexes
Kelland, L. R. (1993) · Critical Reviews in Oncology/Hematology · doi:10.1016/1040-8428(93)90042-3 · Cited by 237
Interactions between mammalian cell DNA and inorganic platinum compounds—I
Pascoe, J. M., & Roberts, J. J. (1974) · Biochemical Pharmacology · doi:10.1016/0006-2952(74)90354-2 · Cited by 236
Cisplatin nephrotoxicity: A review
Daugaard, G., & Abildgaard, U. (1989) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00694330 · Cited by 234
Bellmunt, J., Ribas, A., Eres, N., Albanell, J., Almanza, C., Bermejo, B., Sol�, L.-A., & Baselga, J. (1997) · Cancer · doi:10.1002/(sici)1097-0142(19971115)80:10<1966::aid-cncr14>3.0.co;2-w · Cited by 228
Zwelling, L. A., Michaels, S., Schwartz, H., Dobson, P. P., & Kohn, K. W. (1981) · PubMed · Cited by 210
Ac, P., van Dijk, M., & Lohman, P. H. M. (1984) · PubMed · Cited by 170
Modulation of cis-diamminedichloroplatinum(II) resistance: a review
Timmer-Bosscha, H., Mulder, N., & de Vries, E. (1992) · British Journal of Cancer · doi:10.1038/bjc.1992.249 · Cited by 164
Petrioli, R., Frediani, B., Manganelli, A., Barbanti, G., De Capua, B., De Lauretis, A., Salvestrini, F., Mondillo, S., & Francini, G. (1996) · Cancer · doi:10.1002/(sici)1097-0142(19960115)77:2<344::aid-cncr18>3.0.co;2-1 · Cited by 164
Cross-linking of glutathione to DNA by cancer chemotherapeutic platinum coordination complexes
Eastman, A. R. (1987) · Chemico-Biological Interactions · doi:10.1016/0009-2797(87)90004-4 · Cited by 142
Cisplatin-associated neurotoxicity: can it be prevented?
Alberts, D. S., & Noel, J. K. (1995) · Anti-Cancer Drugs · doi:10.1097/00001813-199506000-00003 · Cited by 126
Morrow, G. R., Hickok, J. T., & Rosenthal, S. N. (1995) · Cancer · doi:10.1002/1097-0142(19950801)76:3<343::aid-cncr2820760302>3.0.co;2-v · Cited by 108
van der Vijgh, W. J. F., & Peters, G. J. (1994) · PubMed · Cited by 105
Browman, G. P., & Cronin, L. (1994) · PubMed · Cited by 101
Stadnicki, S. W., Rw, F., Schaeppi, U. H., & Merriam, P. (1975) · PubMed · Cited by 96
de Andrés, L., Brunet, J., Pousa, A. L., Burgués, J., Vega, M., Tabernero, J. M., Mesía, R., & López, J. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.6.1493 · Cited by 94
Taylor, A., Wiltshaw, E., Gore, M. E., Fryatt, I., & Fisher, C. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.10.2066 · Cited by 77
Schiller, J. H., Storer, B. E., Berlin, J. D., Wittenkeller, J. L., Larson, M. L., Pharo, L. M., Larson, M. L., & Berry, W. R. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.6.1913 · Cited by 71
Hishikawa, Y., Abe, S., Kinugasa, S., Yoshimura, H., Monden, N., Igarashi, M., Tachibana, M., & Nagasue, N. (2009) · Oncology · doi:10.1159/000227714 · Cited by 70
Insights into Mechanisms of Cisplatin Resistance and Potential for Its Clinical Reversal
Gosland, M. P., Lum, B. L., Schimmelpfennig, J., Baker, J., & Doukas, M. A. (1996) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.1996.tb02913.x · Cited by 68
Active Efflux System for Cisplatin in Cisplatin‐resistant Human KB Cells
Fujii, R., Mutoh, M., Niwa, K., et al. (1994) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1994.tb02376.x · Cited by 68
The relationship between cisplatin sensitivity and drug uptake into mammalian cells in vitro
Eichholtz-Wirth, H., & Hietel, B. (1986) · British Journal of Cancer · doi:10.1038/bjc.1986.168 · Cited by 61
A comparison of in vitro platinum-DNA adduct formation between carboplatin and cisplatin
Hongo, A., Shuji, S., Kosuke, A., & Kudo, T. (1994) · International Journal of Biochemistry · doi:10.1016/0020-711x(94)90072-8 · Cited by 57
Vassilev, P. M., Kanazirska, M. P., Charamella, L. J., et al. (1987) · PubMed · Cited by 49
Adjei, A. A., Budihardjo, I. I., Rowinsky, E. K., Kottke, T. J., Svingen, P. A., Buckwalter, C. A., Grochow, L. B., Donehower, R. C., & Kaufmann, S. H. (1997) · PubMed · Cited by 26
Self-citation[Phase II study of carboplatin in ovarian cancer].
Kato, T., Nishimura, H., Yamabe, T., et al. (1988) · PubMed · Cited by 12
Cited by
Cisplatin in cancer therapy: Molecular mechanisms of action
Dasari, S., & Bernard Tchounwou, P. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.07.025 · Cited by 5,537
Ozols, R. F., Bundy, B. N., Greer, B. E., Fowler, J. M., Clarke-Pearson, D., Burger, R. A., Mannel, R. S., DeGeest, K., Hartenbach, E. M., & Baergen, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.02.153 · Cited by 2,032
Cisplatin: The first metal based anticancer drug
Ghosh, S. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.102925 · Cited by 1,751
Bhirde, A. A., Patel, V., Gavard, J., Zhang, G., Sousa, A. A., Masedunskas, A., Leapman, R. D., Weigert, R., Gutkind, J. S., & Rusling, J. F. (2009) · ACS Nano · doi:10.1021/nn800551s · Cited by 853
Marullo, R., Werner, E., Degtyareva, N., Moore, B., Altavilla, G., Ramalingam, S. S., & Doetsch, P. W. (2013) · PLoS ONE · doi:10.1371/journal.pone.0081162 · Cited by 777
“To confirm the essential role of mitochondrial protein synthesis impairment in enhancing cisplatin cytotoxicity, we evaluated the effects of another platinum-based drug, carboplatin, which forms similar types of nDNA lesions, but is substantially less toxic than cisplatin [40].”
Background
Metadata
- Authors
- Go, R. S., & Adjei, A. A.
- Venue
- Journal of Clinical Oncology
- Published
- 1999-01
- Volume
- 17
- Issue
- 1
- Pages
- 409-409
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1907795058
- Cited by
- 697
- References
- 50
- FWCI
- 7.47
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.